Front Row Advisors’s Intellia Therapeutics NTLA Stock Holding History

Front Row Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-100	Closed	-$4K	–	926
2023 Q1	$4K	Hold	100	–	–	﹤0.01%	727
2022 Q4	$3K	Hold	100	–	–	﹤0.01%	742
2022 Q3	$6K	Hold	100	–	–	﹤0.01%	618
2022 Q2	$5K	Hold	100	–	–	﹤0.01%	680
2022 Q1	$7K	Hold	100	–	–	﹤0.01%	645
2021 Q4	$12K	Hold	100	–	–	﹤0.01%	539
2021 Q3	$13K	Hold	100	–	–	0.01%	504
2021 Q2	$14K	Buy	+100	New	+$7.79K	0.01%	496

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Front Row Advisors's NTLA Position: Q2 2023 in Review

Front Row Advisors sold out of Intellia Therapeutics (NTLA) in Q2 2023, closing a stake of 100 shares — an estimated $4K sold.

Front Row Advisors first reported a position in NTLA in Q2 2021 and held it in 8 quarters. The position peaked at $14K in Q2 2021. 290 funds tracked by Wall St. Rank hold NTLA as of Q2 2023.

Front Row Advisors reported no remaining Intellia Therapeutics position as of Q2 2023 after selling out during the quarter.
Front Row Advisors sold 100 Intellia Therapeutics shares in Q2 2023, an estimated $4K.
Front Row Advisors first reported a position in Intellia Therapeutics in Q2 2021 and held it in 8 quarters.
Front Row Advisors's Intellia Therapeutics position peaked at $14K in Q2 2021.
290 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2023.

Based on Front Row Advisors's 13F filing for Q2 2023, filed 15 Aug 2023.